These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 54211)

  • 1. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
    Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
    Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816).
    Lloyd HH; Dulmadge EA; Wilkoff LJ
    Cancer Chemother Rep; 1972 Oct; 56(5):585-91. PubMed ID: 4119906
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
    Chiuten DF; Muggia FM; Johnson RK
    Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Perez LM; Greer S
    Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
    Presant CA; Valeriote F; Vietti TJ
    Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
    DeSimone J; Heller P; Molokie RE; Hall L; Zwiers D
    Am J Hematol; 1985 Mar; 18(3):283-8. PubMed ID: 2579548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 15. On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
    Wentworth DF; Wolfenden R
    Biochemistry; 1975 Nov; 14(23):5099-105. PubMed ID: 53069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities for the clinical use of 5-azacytidine].
    Veselý J; Cihák A
    Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
    Presant CA; Vietti T; Valeriote F
    Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).
    Furner RL; Mellett LB
    Cancer Chemother Rep; 1975; 59(4):717-20. PubMed ID: 809135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine.
    Beisler JA; Abbasi MM; Driscoll JS
    Cancer Treat Rep; 1976 Nov; 60(11):1671-4. PubMed ID: 66095
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
    Momparler RL; Veselý J; Momparler LF; Rivard GE
    Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.